TABLE 3.

Impact of mNGS on antimicrobial treatment for patients with PJP.

Modifications [n (%)]	PJP patients (n = 122)	Non-PJP patients (n = 67)
Antimicrobial treatment change	109 (89.3)	50 (74.6)
Add TMP-SMZ only	43 (35.2)	4 (5.9)
Add caspofungin only	16 (13.1)	0 (0)
Add TMP-SMZ + caspofungin	15 (12.3)	0 (0)
Add agent	56 (45.9)	45 (67.2)
Remove agent	0 (0)	1 (1.5)
No change	13 (10.7)	17 (25.4)

TMP-SMZ, trimethoprim-sulfamethoxazole; remove agent, the number of antimicrobial agent types reduced after the report of mNGS results; add agent, the number of antimicrobial agent types increased after the report of mNGS results.